Neostigmine methyl sulfate

3-(N,N-Dimethylcarbamoyloxy)-N,N,N,-trimethylanilinium methyl sulfate
Empirical Formula (Hill Notation):
CAS Number:
Molecular Weight:
EC Number:
MDL number:
PubChem Substance ID:
Pricing and availability is not currently available.

Quality Level

storage temp.


SMILES string




InChI key


Gene Information

human ... ACHE(43)

Looking for similar products? Visit Product Comparison Guide

Biochem/physiol Actions

Reversible inhibitor of acetylcholinesterase that is similar to eserine, but does not cross the blood-brain barrier.


Skull and crossbonesHealth hazard

Signal Word


Target Organs

Respiratory system

Personal Protective Equipment

dust mask type N95 (US),Eyeshields,Gloves


UN 2811 6.1 / PGII

WGK Germany


Flash Point(F)

Not applicable

Flash Point(C)

Not applicable

C T Sadashiva et al.
Bioorganic & medicinal chemistry letters, 16(15), 3932-3936 (2006-06-01)
The cholinergic hypothesis of Alzheimer's disease (AD) has spurred the development of numerous structural classes of compounds with different pharmacological profile aimed at increasing central cholinergic neurotransmission. Thus proving a symptomatic treatment for this disease are cholinomimetics with the pharmacological...
Qian-Sheng Yu et al.
Bioorganic & medicinal chemistry, 18(13), 4687-4693 (2010-07-16)
The N-monophenylcarbamate analogues of neostigmine methyl sulfate (6) and pyridostigmine bromide (8) together with their precursors (5), (7), and the N(1)-methylammonium analogues of (-)-phenserine (12), (-)-tolserine (14), (-)-cymserine (16) and (-)-phenethylcymserine (18) were synthesized to produce long-acting peripheral inhibitors of...
Michael Benatar et al.
The Cochrane database of systematic reviews, 12, CD005081-CD005081 (2012-12-14)
Approximately 50% of people with myasthenia gravis present with purely ocular symptoms, so called ocular myasthenia. Of these between 50% to 60% develop generalized disease, most within two years. Their management is controversial. This is an update of a review...
G V Cammu et al.
Anaesthesia and intensive care, 40(6), 999-1006 (2012-12-01)
Six years ago, a study performed in our department reported that the incidence of postoperative residual curarisation (PORC) was 39%. The reassessment of neuromuscular monitoring and reversal of neuromuscular block in routine anaesthetic practice is relevant now that sugammadex has...
Jakub Fichna et al.
Pharmacological reports : PR, 64(5), 1146-1154 (2012-12-15)
Animal models of visceral pain have gained much attention as an important tool to elucidate the possible mechanisms underlying functional gastrointestinal (GI) disorders. Here we report the development of a new, minimally invasive behavioral model of abdominal pain induced by...

Our team of scientists has experience in all areas of research including Life Science, Material Science, Chemical Synthesis, Chromatography, Analytical and many others.

Contact Technical Service

Social Media

LinkedIn icon
Twitter icon
Facebook Icon
Instagram Icon


Research. Development. Production.

We are a leading supplier to the global Life Science industry with solutions and services for research, biotechnology development and production, and pharmaceutical drug therapy development and production.

© 2021 Merck KGaA, Darmstadt, Germany and/or its affiliates. All Rights Reserved.

Reproduction of any materials from the site is strictly forbidden without permission.